Abu Dhabi, UAE: Cleveland Clinic Abu Dhabi has introduced the Middle East’s first robotically-assisted bronchoscopy platform, enabling physicians to accurately biopsy small, hard-to-reach lung nodules that are often the earliest signs of lung cancer.
The MONARCH™ platform provides enhanced precision for minimally invasive diagnosis, helping improve early detection of Stage 1 lung cancer, where the five-year survival rate exceeds 70%. The technology can also diagnose metastatic lung cancer, benign lung nodules, tuberculosis, and inflammatory lung diseases.
Click here to join our WhatsApp channel here
Supported by the Department of Health – Abu Dhabi, the platform reflects the emirate’s commitment to advancing predictive and precision healthcare through innovative medical technologies.
Dr. Georges-Pascal Haber, Chief Executive Officer at Cleveland Clinic Abu Dhabi, said, “Introducing robotically-assisted bronchoscopy reflects Cleveland Clinic Abu Dhabi’s continued commitment to bringing transformative, precision-led technologies to the Middle East. By investing in advanced, technology-enabled solutions, we are redefining patients’ experience through safer, less invasive care while also enhancing diagnostic accuracy.”
The hospital noted that the robotic platform could also support future robotic interventions for lung cancer treatment, including ablation therapies.
Also read: New Access Strategy Announced for Investigational Monthly HIV Prevention Pill
